Decoding the Dilemma: A Comprehensive Approach to Diagnosing and Managing Elevated Liver Enzymes in Clinical Practice
OthersPage Navigation
Introduction
Elevated Liver Enzymes (ELE) often present a diagnostic challenge for clinicians due to the myriad of potential causes. This brief review aims to provide a comprehensive approach to the diagnosis and management of ELE.
Diagnosis
Diagnosis of ELE begins with a thorough history and physical examination. Key factors to consider include alcohol consumption, medication use, and exposure to hepatotoxic substances. Laboratory investigations should include a complete liver panel, coagulation studies, and serologic tests for viral hepatitis.
Management
Management of ELE primarily focuses on addressing the underlying cause. This may involve lifestyle modifications, medication changes, or specific treatments for identified liver diseases. Close monitoring of liver function tests is essential to assess response to treatment and detect any potential complications.
Role of Imaging
Imaging studies, such as ultrasound or CT scan, can provide valuable information about the liver's structure and help identify conditions such as fatty liver disease or cirrhosis. However, these should be reserved for cases where initial investigations are inconclusive.
Conclusion
Diagnosing and managing ELE requires a systematic approach that includes thorough history taking, appropriate laboratory and imaging investigations, and targeted treatment strategies. By adopting such an approach, clinicians can effectively manage this common clinical dilemma.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
2.
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
3.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
4.
In early dementia, SSRIs enhance cognition and major depression.
5.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
1.
Oncologic Emergencies: Diagnosis and Treatment
2.
Strategic Standards in Hematology for Specialists
3.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
4.
Advanced Breakthroughs in Hematology and Patient Outcomes
5.
Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part IX
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge